Daria G. Husni

Under the agreement, the companies will discover and develop drug candidates targeting two ion channels linked to neurological disorders.

A look into the latest developments in biopharmaceutical manufacturing and facilities.

Adzynma provides a replacement for low levels of the ADAMTS13 enzyme in patients with congenital thrombotic thrombocytopenic purpura.

This is the second biologic approved to treat HS, a painful and reoccurring skin disease.

PENBRAYA combines components from two meningococcal vaccines, Trumenba and Nimenrix.

As CMOs continue to invest in cell culture capacity, some are expected to surpass top in-house companies.

The report indicates a rise in biotech funding and subsequent growth for pharma contract services.

Wheeler plans to use the facility to bolster its mission in helping fledgling biotech innovators and startups accelerate their development at an equitable price.

Mirati’s focus on breakthrough cancer treatments will bolster Bristol Myers Squibb’s oncology portfolio.

Spinning off Sandoz allows Novartis to focus on the areas of cardiovascular, immunology, renal and metabolic, and oncology.